The more I look at the board, the less confident I am becoming...
We went from a board, where virtually everyone was highly qualified in the pharma industry, to a board where virtually nobody has any operational experience:
Bonfiglio - Sarissa's Chief Compliance Officer - she's basically a bookkeeper and compliance person for Sarissa. And she has a day job.
DiPaolo - Sarissa's General Counsel - he specializes in legal work for the investment industry. And he has a day job.
Horn - He's an investment advisor. And has a day job.
Sterling - a private investor.
Cohen - Marginally qualified, but he's a professor and senior attending physician. So his involvement will be limited.
Sullivan - Qualified
O'Conner - Qualified
Kostas - Qualified, Sarissa employee
How the hell does this slate of officers appear more qualified or able to navigate Amarin out of the Black Hole we are in, versus the officers we had? Basically, we've got three, maybe four people on the board that will be pulling most of the weight. And we lost our CEO, who's entire background was in Europe, and replaced him with someone that can't find London on a map. Love him or hate him, he knew WAY more about the business than this lineup.
Sorry, but Denner wildly missed the mark on his strategy with Amarin. And everyone can chime in with the *only* sad argument they have left..."yeah, but Denner put his money on the table!"....OK. Clarification, he put his investor's money on the table. And that doesn't make this situation any better. All that makes him is a glorified investment manager that understands the healthcare industry.
If we thought we were in trouble before, we are phucked now. The old board is probably laughing their asses off right now.
Sorry to be blunt, but we are at the stage where we are now praying for Vascepa to cure Alzhemier's to save us.
Market Data 
Markets 
AI
